Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

humoral hypercalcemia of malignancy - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

humoral hypercalcemia of malignancy

MONDO:0043455

Also known as:hypercalcemia of malignancyhhmmahc

Overview

Hypercalcemia generally develops as a late complication of malignancy; its appearance has grave prognostic significance. It remains unclear, however, whether death is associated with hypercalcemic crisis (uncontrolled or recurrent progressive hypercalcemia) or with advanced disease. Symptoms include central nervous system impairment such as delirium with prominent symptoms of personality change, cognitive dysfunction, disorientation, incoherent speech, and psychotic symptoms such as hallucinations and delusions, smooth muscle hypotonicity, and altered cardiovascular function.

Treatments4 FDA approved, newest 2025

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

4 FDA-approved treatments are available for humoral hypercalcemia of malignancy, including DENOSUMAB-BMWO (STOBOCLO, approved 2025), DENOSUMAB (BILPREVDA, approved 2025), and ZOLEDRONIC ACID (ZOLEDRONIC ACID, approved 2013). An additional 4 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for humoral hypercalcemia of malignancy.

74 publications have been identified in PubMed for humoral hypercalcemia of malignancy. Research spans Case Report / Case Series (61%), Review / Meta-Analysis (18%), and Epidemiology / Natural History (8%).

Research Type	Count	% of Total
Patient case studies	43	61%

Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 12:22 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of STOBOCLO for managing humoral hypercalcemia of malignancy?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Zometa, Zabel	Zoledronate	Novartis Pharmaceuticals Corp.	2000	2008	Designated (drug approved for other indication)
Disodium clodronate	Disodium clodronate	Discovery Experimental & Development, Inc.	1993	—	Designated
Ganite	Gallium nitrate injection	Solopak Pharmaceutical Co.	1988	1998	Withdrawn
Didronel	Etidronate disodium	MGI Pharma, Inc.	1986	1994	Designated (drug approved for other indication)

Kisho

humoral hypercalcemia of malignancy

Overview

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

humoral hypercalcemia of malignancy

Overview

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications